Clinical Trials Logo

Clinical Trial Summary

Neuromyelitis Optica (NMO)/ Neuromyelitis Optica Spectrum Disorders (NMOSD) is an immune-mediated inflammatory demyelinating disease of the central nervous system mainly involving optic nerve and spinal cord. It is clinically characterized by simultaneous or sequential involvement of the optic nerve and spinal cord, presenting a progressive or remission and relapse course, which can lead to paralysis and blindness.

The objective of this study is to provide evidence regarding treat effects and factors related to prognosis which will help physicians better evaluable risk-benefit in NMOSD management and improve patients' outcome.


Clinical Trial Description

Neuromyelitis Optica (NMO)/ Neuromyelitis Optica Spectrum Disorders (NMOSD) is an immune-mediated inflammatory demyelinating disease of the central nervous system mainly involving optic nerve and spinal cord. It is clinically characterized by simultaneous or sequential involvement of the optic nerve and spinal cord, presenting a progressive or remission and relapse course, which can lead to paralysis and blindness.

Globally, there is no solid data available for the diagnosis, treatment and prognosis of patients with acute Neuromyelitis Optica Spectrum Disorders (NMOSD) attack, particularly very rare data from prospective studies. This is a multicenter, prospective, real-world cohort study in patients with acute NMOSD attack in China.

Baseline data for approximately 200 patients with acute NMOSD attack from approximately 4 centers will be collected. Patients with acute NMOSD attack (including first episodes and relapses) whose expansile disability status score (EDSS ) ≥ 2 points at baseline will be eligible to be further included in prospective study cohort for analysis of treatment effects and prognosis.

The objective of this study is to provide evidence regarding treat effects and factors related to prognosis which will help physicians better evaluable risk-benefit in NMOSD management and improve patients' outcome. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04101058
Study type Observational
Source Third Affiliated Hospital, Sun Yat-Sen University
Contact
Status Enrolling by invitation
Phase
Start date January 21, 2019
Completion date June 30, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT02836327 - Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders N/A
Recruiting NCT04146285 - A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders Phase 1
Not yet recruiting NCT06068829 - Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders
Recruiting NCT05204459 - MS-ResearchBiomarkerS
Completed NCT03350633 - Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Phase 2/Phase 3
Completed NCT04388072 - An Diagnostic Cohort on AQP4-Immunoglobulin G Detection Kit
Completed NCT05871658 - Efficacy of Electroacupuncture in NMOSD Patients With Pain: Study Protocol N/A
Recruiting NCT02021825 - Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Phase 4
Recruiting NCT06249438 - A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy Phase 1
Not yet recruiting NCT06413654 - A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) Phase 2/Phase 3
Recruiting NCT03330418 - A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders Phase 3
Enrolling by invitation NCT02809079 - Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Phase 4
Recruiting NCT02889965 - The French Multiple Sclerosis Registry N/A
Completed NCT02850705 - The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS)
Completed NCT04670770 - An Open Label Study of the Effects of SHR1459 in NMOSDs Patients Phase 2
Not yet recruiting NCT06212245 - A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders Phase 4
Completed NCT03062579 - A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Phase 1/Phase 2
Recruiting NCT05730699 - Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE) Phase 3